After years of escalating fatalities and pressure from the FDA, Janssen announced that it would voluntarily stop marketing Propulsid in the United States beginning July 14, 2000. The drug is still used for treatment. However, patients must now meet an even more stringent level of criteria. Physicians must assess each patient and then confirm that there is no alternative therapy, there is no history of cardiac problems, the patient is not taking any conflicting drugs, and the patient took an electrocardiogram and blood tests.
- About US
- Our Practice Areas